Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Indocyanine Green Angiography of Well-Defined Plaque Choroidal Neovascularization in Age-Related Macular Degeneration

Indocyanine Green Angiography of Well-Defined Plaque Choroidal Neovascularization in Age-Related... ObjectiveTo determine the natural course of well-defined plaque choroidal neovascularization (CNV) using indocyanine green angiography.MethodsTwo ophthalmologists, experts in macular diseases and indocyanine green angiography, examined 40 eyes with exudative age-related macular degeneration and a well-defined plaque CNV using complete ophthalmoscopic evaluation, fluorescein angiography, and indocyanine green angiography. The increase in the size of the plaques was analyzed using multivariate analysis, in relation to the worsening of visual acuity, with adjustment for age, sex, and length of follow-up.ResultsMean follow-up was 13.5 months (median, 11 months). Initial and final mean visual acuity were 20/46 (median, 20/50) and 20/65 (median, 20/100), respectively. The mean initial size of the plaque was 6.62 mm2(median, 6.20 mm2), and the mean final size was 10.40 mm2(median, 9.76 mm2). The enlargement was statistically significant (P<.001).ConclusionsWe found that plaque CNV tends to become larger with time, the enlargement reaching about 40% in 1 year of follow-up. The resulting loss of visual acuity, however, is not significant, and is slightly correlated with the extension of the lesion; it also does not appear to be directly related to sex.THE EXUDATIVE form of age-related macular degeneration (ARMD) is marked by occult choroidal neovascularization (O-CNV), not clearly detectable by fluorescein angiography (FA) in 87% of cases.Indocyanine green angiography (ICGA) identifies 90% of O-CNV, dividing it largely between focal CNV (29%) and plaque CNV (61%); the remaining 10% are ill defined. Plaque CNV can be further divided according to ICGA appearance of being well defined (27% of all CNV) and poorly defined (34% of all CNV).Little is known about the natural history of these plaques, which some reports describe as slowly developing, not very aggressive CNV, with fairly good visual acuity (VA),and others describe as quickly developing, with a poor natural history.Our aim was to analyze the natural course of well-defined plaque CNV in relation to their enlargement, VA, and length of follow-up.MATERIALS AND METHODSWe examined 383 eyes of 355 consecutive patients with exudative ARMD and occult new vessels on FA; 117 were men and 238 were women. The mean age was 73.4 years (range, 55-92 years). Indocyanine green angiography failed to identify CNV in 122 eyes (32%); 132 eyes (34%) had focal CNV; and 129 eyes (34%) showed plaque CNV, ill-defined in 74 (57%) of the 129 eyes and well-defined in 55 (43%). Therefore, in our prospective study, we examined 55 eyes of 52 patients, 22 men and 30 women. At the end of follow-up, 12 patients (15 eyes) were excluded; 2 of them (3 eyes) died, 5 (6 eyes) had evident subfoveal CNV (and an ill-defined plaque CNV, not evaluable by the 2 observers), and 5 (6 eyes) did not return for visits. We therefore considered 40 eyes of 40 patients, 17 men and 23 women (mean±SD age, 72 ± 5.7 years) with exudative ARMD, with O-CNV on FA and well-defined plaque CNV on ICGA. There was no FA evidence of pigment epithelial detachment. All patients underwent a complete clinical ophthalmologic examination, including best corrected VA (recorded on standard Snellen charts), color retinography, FA, and ICGA. Fluorescein angiography and ICGA were performed no more than 3 days apart, and frequently on the same day. Informed consent was obtained. The angiographic examinations were performed using a complete high-resolution digital system (Topcon 1024 IMAGEnet System; Topcon Corporation, Tokyo, Japan) with a fundus camera (TRC-50IA; Topcon Corporation). For ICGA, 25 mg of indocyanine green (Infracyanine) diluted in 10 mL of aqueous solvent was injected into the antecubital vein; early (from choroidal filling to the retinal venous phase, up to 5 minutes), middle (10-15 minutes), and late phases (30-40 minutes) were recorded for each patient.Inclusion criteria were ages 55 years or older, recent onset of symptoms (decrease of VA and/or metamorphopsia no more than 3 months before entry), ARMD without a well-defined CNV on FA, a clearly outlined area of ICGA hyperfluorescence (larger than 1 disc area) presumed to be a well-defined plaque CNV, initial VA of greater than 20/200, and minimum follow-up of 6 months. Exclusion criteria were presence of fibrous proliferation, previous macular laser treatment or surgery, no clear ocular media, and other disease affecting the posterior pole.Well-defined plaque is characterized by a hyperfluorescent lesion on ICGA larger than 1 disc area, with sharp borders, well detectable in the middle and late angiographic phases.Two ophthalmologists, both experts in angiography and macular pathology (A.P. and U.I.), independently outlined the plaque in the late phase of ICGA with the use of the area measurement device of a complete high-resolution digital system (Topcon IMAGEnet 1024 System; Topcon Corporation) (Figure 1). Neither knew the patients' names or the examination dates.Figure 1.The plaque choroidal neovascularization outlined by observer A (A) and observer B (B) with the use of the area measurement device of a complete high-resolution digital system (Topcon IMAGEnet 1024 System; Topcon Corporation, Tokyo, Japan).As the variables were not normally distributed (Shapiro-Wilks statistic), nonparametric tests were used. Agreement between observers was assessed using the Spearman coefficient to correlate measures taken by both independent observers. The signed rank test was used to investigate whether VA and the size of the plaques changed after follow-up. To investigate the independent effects of increasing severity of plaques, age, sex, and follow-up on the worsening of VA, multiple stepwise regression was performed after rank transformation of the dependent-variable VA change. Partial R2expressed the contribution of each variable. Classes of plaque increase were set up on the basis of quartiles of distribution, and the Kruskal-Wallis test was used to compare variables for the different classes of plaque increase. Analyses were performed using the SAS System.Unless otherwise specified, data are given as mean±SD.RESULTSThe correlation coefficients between the plaque measurements taken by both observers were 0.91 (P<.001) at baseline and 0.95 (P<.001) at the final examination. Mean follow-up was 13.5±8.5 months (range, 6-36 months; median, 11 months). Initial and final mean VA were 20/46±20/95 (median, 20/50) and 20/65±20/83 (median, 20/100), respectively, with a mean change of 20/166±20/105 (median, 20/200), which was statistically significant (P<.001).The mean initial size of the plaque was 6.62 ± 3.71 mm2(median, 6.20 mm2), and the mean final size was 10.40 ± 6.40 mm2(median, 9.76 mm2), with a mean change of 3.78 ± 4.80 mm2(median, 2.65 mm2). The enlargement was statistically significant (P<.001).When the effect of the increase in the plaque size on the worsening of VA was investigated using multivariate analysis with adjustment for age, sex, and follow-up time, the increase was slightly, but not significantly, correlated with VA loss (partial R2=0.06; P=.09). Age (partial R2=0.12; P=.03) and length of follow-up (partial R2=0.11; P=.02) were the variables most closely correlated with the VA changes, being greater at higher VA change. Women had less loss of VA, but the difference was not significant (partial R2=0.09; P=.07).Table 1presents patient data by quartiles of change in plaque size.Patient Data by Quartiles of Percentage of Change in Plaque Size*VariablesChange, %P≤20.0 (n=10)20.1-40.0 (n=10)40.1-84.0 (n=10)>84.0 (n=10)Age, y71.3 ± 6.8 (71.5)72.1 ± 6.9 (73)71.7 ± 3.8 (71.5)73.3 ± 5.5 (73).80Follow-up, mo10.3 ± 6.3 (6)15.9 ± 11.0 (11)14.3 ± 8.1 (14)13.3 ± 8.1 (10.5).40Initial plaque size, mm27.4 ± 5.2 (5.89)8.6 ± 2.6 (8.80)5.4 ± 2.4 (5.60)5.1 ± 3.2 (3.80).10Final plaque size, mm27.6 ± 5.6 (6.05)11.1 ± 3.2 (11.0)8.6 ± 4.1 (8.60)14.3 ± 8.4 (11.30).15Initial VA20/56 ± 20/74 (20/66)20/47 ± 20/133 (20/57)20/46 ± 20/87 (20/44)20/40 ± 20/100 (20/33).30Final VA20/74 ± 20/71 (20/160)20/66 ± 20/83 (20/89)20/65 ± 20/95 (20/80)20/54 ± 20/77 (20/66).60*Data are given as mean ± SD (median). VA indicates visual acuity. Comparisons were made using the Kruskal-Wallis test.COMMENTFreund et alreported that approximately 13% of the CNV lesions they studied were well defined by FA, with the remaining 87% considered occult. Indocyanine green angiography is a new technique that enhances imaging of the choroid and has been shown to be useful in better delineating O-CNV. The characteristics of the dye (fluorescent in the near infrared range and almost completely protein bound) have permitted better investigation of the choroidal abnormalities through the pigmentary epithelium, hemorrhages, and turbid fluids.Indocyanine green angiography identifies the O-CNV better.It delineates focal, plaque, or mixed (focal and plaque) CNV.Focal CNV (29% of cases) is a bright, well-defined, hyperfluorescent lesion smaller than 1 disc area. Plaque is a large area of hyperfluorescence bigger than 1 disc area that may be well defined (27% of patients) or poorly defined (34% of patients).Well-defined plaques are moderately hyperfluorescent lesions with sharp borders, and they usually appear in the late phase of the ICGA, without any dye staining. Poorly defined plaques show irregular, unclear edges and often leak dye during the late phase of the examination. Plaque CNV are not usually eligible for laser treatment because of their size and frequent subfoveal location. However, ICGA has not yet permitted an evaluation of the natural course of the different types of CNV. Furthermore, new forms of presumed CNV (polypoidal CNV) are being evaluated.Evidence that plaque corresponds to CNV was provided by Chang et aland Lauer et al.These histological studies showed that plaque consists of thick fibrovascular tissue within the Bruch membrane. However, clinicopathological data on these lesions is scant, and questions remain about their histological characteristics.Poor natural evolution of CNV in ARMD is well known.Occult CNV also has a bad prognosis.We found no contributions of the natural history of focal CNV detected by ICGA, because most investigators considered ICGA-guided laser treatment effective. The natural course of hyperfluorescent plaque lesions is better known, because they are not usually treated, although results are far from uniform. In 1992, Yannuzzi et alfirst showed plaque lesions, by means of ICGA, as a vascularized retinal pigment epithelium (RPE) often associated with good VA and very slow progression; Guyer et al,however, found the natural history of plaques discouraging, with an increase of the plaque correlated with decreased VA and increased exudation.Our study confirmed that plaques tend to get bigger(Figure 2and Figure 3). We noted an increase of about 40% during a median follow-up of 11 months. There was significant VA loss during this period, but the enlargement of the plaque could explain only 6% of the variability of this loss, and multivariate analysis found the relationship was not statistically significant, probably because of the small sample size. No correlation was found between VA decline and other associated alterations such as subretinal hemorrhages and elevation of the neovascularization. There was, however, a significant correlation between patients' age and VA loss, ie, the older the patient, the worse the VA. We can explain this by the more diffuse alteration of RPE and choroid in older patients, which may affect VA. Also, greater loss of VA was seen with longer follow-up. The worsening of VA, weakly correlated to the plaque increase, was progressive; at the onset, plaque CNV was located subretinally, and retinal changes were usually slight. As the plaque became larger, however, it caused chronic damage to the RPE and neurosensorial retina.Figure 2.Red-free retinography (A) and fluorescein angiography (FA) (B) show an exudative age-related macular degeneration. A plaque choroidal neovascularization is visible in the late phases of indocyanine green angiography (ICGA) as a hyperfluorescent, well-defined area (C). Red-free retinography (D), FA (E), and ICGA (F) were performed 7 months later. The ICGA image shows approximately 300% enlargement of the plaque. Visual acuity at the beginning and 7 months later was 20/40 and 20/32, respectively.Figure 3.Red-free retinography (A), fluorescein angiography (FA) (B), and indocyanine green angiography (ICGA) (C) of an exudative maculopathy, with a well-defined plaque choroidal neovascularization visible on ICGA. D, E, and F, Red-free retinography, FA, and ICGA, respectively, 9 months later. Compared with FA (E), ICGA (F) shows considerable enlargement of the plaque. Visual acuity was unchanged (20/32).CONCLUSIONSWell-defined plaques tend to enlarge in time, growing by about 40% during 1 year of follow-up. The loss of VA is slightly, but not significantly, correlated to plaque enlargement. Plaque lesions, therefore, appear to be a less aggressive, slower developing form of CNV, with a relatively good prognosis, although the natural tendency is to worsen. Further follow-up will be necessary to establish their course, considering those that develop into well-defined, classic CNV and those that proceed to natural involution.KBFreundLAYannuzziJASorensonAge-related macular degeneration and choroidal neovascularization.Am J Ophthalmol.1993;115:786-791.DRGuyerLAYannuzziJSSlakterClassification of choroidal neovascularization by digital indocyanine green videoangiography.Ophthalmology.1996;103:2054-2060.LAYannuzziJSSlakterJASorensonDigital indocyanine green videoangiography and choroidal neovascularization.Retina.1992;12:191-223.Not AvailableSAS System Release[computer program&rsqb;.Version 6.10, 1991-1994. Cary, NC: SAS Institute Inc; 1994.LAYannuzziJASorensonDRGuyerIndocyanine green videoangiography: current status.Eur J Ophthalmol.1994;4:69-81.APeceUIntroiniGBolognesiRBrancatoIndocyanine green angiography in age-related macular degeneration with occult neovascularization.Ophthalmologica.1998;212:295-300.TSChangKBFreundZDe La CruzClinicopathologic correlation of choroidal neovascularization demonstrated by indocyanine green angiography in a patient with retention of good vision for almost four years.Retina.1994;14:114-124.AKLauerDJWilsonMLKleinClinicopathologic correlation of fluorescein and indocyanine green videoangiography in occult choroidal neovascularization (abstract).Invest Ophthalmol Vis Sci.1997;38(suppl):442.SBBresslerNMBresslerSLFineNatural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration.Am J Ophthalmol.1982;93:157-163.GSoubraneGCoscasCFrancoisFKoenigOccult subretinal new vessels in age-related macular degeneration: natural history and early laser treatment.Ophthalmology.1990;97:649-657.GBolognesiRBrancatoAPeceIndocyanine green angiography (ICGA) follow-up of plaque choroidal neovascularization in age-related macular degeneration (abstract).Invest Ophthalmol Vis Sci.1997;38(suppl):445.Accepted for publication December 9, 1999.Reprints: Rosario Brancato, MD, Department of Ophthalmology and Visual Sciences, Scientific Institute HS Raffaele, University of Milano, Via Olgettina 60, 20132 Milano, Italy (e-mail: brancato.rosario@hsr.it). http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Ophthalmology American Medical Association

Indocyanine Green Angiography of Well-Defined Plaque Choroidal Neovascularization in Age-Related Macular Degeneration

Loading next page...
 
/lp/american-medical-association/indocyanine-green-angiography-of-well-defined-plaque-choroidal-V6gepmp9m3
Publisher
American Medical Association
Copyright
Copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6165
eISSN
2168-6173
DOI
10.1001/archopht.118.5.630
Publisher site
See Article on Publisher Site

Abstract

ObjectiveTo determine the natural course of well-defined plaque choroidal neovascularization (CNV) using indocyanine green angiography.MethodsTwo ophthalmologists, experts in macular diseases and indocyanine green angiography, examined 40 eyes with exudative age-related macular degeneration and a well-defined plaque CNV using complete ophthalmoscopic evaluation, fluorescein angiography, and indocyanine green angiography. The increase in the size of the plaques was analyzed using multivariate analysis, in relation to the worsening of visual acuity, with adjustment for age, sex, and length of follow-up.ResultsMean follow-up was 13.5 months (median, 11 months). Initial and final mean visual acuity were 20/46 (median, 20/50) and 20/65 (median, 20/100), respectively. The mean initial size of the plaque was 6.62 mm2(median, 6.20 mm2), and the mean final size was 10.40 mm2(median, 9.76 mm2). The enlargement was statistically significant (P<.001).ConclusionsWe found that plaque CNV tends to become larger with time, the enlargement reaching about 40% in 1 year of follow-up. The resulting loss of visual acuity, however, is not significant, and is slightly correlated with the extension of the lesion; it also does not appear to be directly related to sex.THE EXUDATIVE form of age-related macular degeneration (ARMD) is marked by occult choroidal neovascularization (O-CNV), not clearly detectable by fluorescein angiography (FA) in 87% of cases.Indocyanine green angiography (ICGA) identifies 90% of O-CNV, dividing it largely between focal CNV (29%) and plaque CNV (61%); the remaining 10% are ill defined. Plaque CNV can be further divided according to ICGA appearance of being well defined (27% of all CNV) and poorly defined (34% of all CNV).Little is known about the natural history of these plaques, which some reports describe as slowly developing, not very aggressive CNV, with fairly good visual acuity (VA),and others describe as quickly developing, with a poor natural history.Our aim was to analyze the natural course of well-defined plaque CNV in relation to their enlargement, VA, and length of follow-up.MATERIALS AND METHODSWe examined 383 eyes of 355 consecutive patients with exudative ARMD and occult new vessels on FA; 117 were men and 238 were women. The mean age was 73.4 years (range, 55-92 years). Indocyanine green angiography failed to identify CNV in 122 eyes (32%); 132 eyes (34%) had focal CNV; and 129 eyes (34%) showed plaque CNV, ill-defined in 74 (57%) of the 129 eyes and well-defined in 55 (43%). Therefore, in our prospective study, we examined 55 eyes of 52 patients, 22 men and 30 women. At the end of follow-up, 12 patients (15 eyes) were excluded; 2 of them (3 eyes) died, 5 (6 eyes) had evident subfoveal CNV (and an ill-defined plaque CNV, not evaluable by the 2 observers), and 5 (6 eyes) did not return for visits. We therefore considered 40 eyes of 40 patients, 17 men and 23 women (mean±SD age, 72 ± 5.7 years) with exudative ARMD, with O-CNV on FA and well-defined plaque CNV on ICGA. There was no FA evidence of pigment epithelial detachment. All patients underwent a complete clinical ophthalmologic examination, including best corrected VA (recorded on standard Snellen charts), color retinography, FA, and ICGA. Fluorescein angiography and ICGA were performed no more than 3 days apart, and frequently on the same day. Informed consent was obtained. The angiographic examinations were performed using a complete high-resolution digital system (Topcon 1024 IMAGEnet System; Topcon Corporation, Tokyo, Japan) with a fundus camera (TRC-50IA; Topcon Corporation). For ICGA, 25 mg of indocyanine green (Infracyanine) diluted in 10 mL of aqueous solvent was injected into the antecubital vein; early (from choroidal filling to the retinal venous phase, up to 5 minutes), middle (10-15 minutes), and late phases (30-40 minutes) were recorded for each patient.Inclusion criteria were ages 55 years or older, recent onset of symptoms (decrease of VA and/or metamorphopsia no more than 3 months before entry), ARMD without a well-defined CNV on FA, a clearly outlined area of ICGA hyperfluorescence (larger than 1 disc area) presumed to be a well-defined plaque CNV, initial VA of greater than 20/200, and minimum follow-up of 6 months. Exclusion criteria were presence of fibrous proliferation, previous macular laser treatment or surgery, no clear ocular media, and other disease affecting the posterior pole.Well-defined plaque is characterized by a hyperfluorescent lesion on ICGA larger than 1 disc area, with sharp borders, well detectable in the middle and late angiographic phases.Two ophthalmologists, both experts in angiography and macular pathology (A.P. and U.I.), independently outlined the plaque in the late phase of ICGA with the use of the area measurement device of a complete high-resolution digital system (Topcon IMAGEnet 1024 System; Topcon Corporation) (Figure 1). Neither knew the patients' names or the examination dates.Figure 1.The plaque choroidal neovascularization outlined by observer A (A) and observer B (B) with the use of the area measurement device of a complete high-resolution digital system (Topcon IMAGEnet 1024 System; Topcon Corporation, Tokyo, Japan).As the variables were not normally distributed (Shapiro-Wilks statistic), nonparametric tests were used. Agreement between observers was assessed using the Spearman coefficient to correlate measures taken by both independent observers. The signed rank test was used to investigate whether VA and the size of the plaques changed after follow-up. To investigate the independent effects of increasing severity of plaques, age, sex, and follow-up on the worsening of VA, multiple stepwise regression was performed after rank transformation of the dependent-variable VA change. Partial R2expressed the contribution of each variable. Classes of plaque increase were set up on the basis of quartiles of distribution, and the Kruskal-Wallis test was used to compare variables for the different classes of plaque increase. Analyses were performed using the SAS System.Unless otherwise specified, data are given as mean±SD.RESULTSThe correlation coefficients between the plaque measurements taken by both observers were 0.91 (P<.001) at baseline and 0.95 (P<.001) at the final examination. Mean follow-up was 13.5±8.5 months (range, 6-36 months; median, 11 months). Initial and final mean VA were 20/46±20/95 (median, 20/50) and 20/65±20/83 (median, 20/100), respectively, with a mean change of 20/166±20/105 (median, 20/200), which was statistically significant (P<.001).The mean initial size of the plaque was 6.62 ± 3.71 mm2(median, 6.20 mm2), and the mean final size was 10.40 ± 6.40 mm2(median, 9.76 mm2), with a mean change of 3.78 ± 4.80 mm2(median, 2.65 mm2). The enlargement was statistically significant (P<.001).When the effect of the increase in the plaque size on the worsening of VA was investigated using multivariate analysis with adjustment for age, sex, and follow-up time, the increase was slightly, but not significantly, correlated with VA loss (partial R2=0.06; P=.09). Age (partial R2=0.12; P=.03) and length of follow-up (partial R2=0.11; P=.02) were the variables most closely correlated with the VA changes, being greater at higher VA change. Women had less loss of VA, but the difference was not significant (partial R2=0.09; P=.07).Table 1presents patient data by quartiles of change in plaque size.Patient Data by Quartiles of Percentage of Change in Plaque Size*VariablesChange, %P≤20.0 (n=10)20.1-40.0 (n=10)40.1-84.0 (n=10)>84.0 (n=10)Age, y71.3 ± 6.8 (71.5)72.1 ± 6.9 (73)71.7 ± 3.8 (71.5)73.3 ± 5.5 (73).80Follow-up, mo10.3 ± 6.3 (6)15.9 ± 11.0 (11)14.3 ± 8.1 (14)13.3 ± 8.1 (10.5).40Initial plaque size, mm27.4 ± 5.2 (5.89)8.6 ± 2.6 (8.80)5.4 ± 2.4 (5.60)5.1 ± 3.2 (3.80).10Final plaque size, mm27.6 ± 5.6 (6.05)11.1 ± 3.2 (11.0)8.6 ± 4.1 (8.60)14.3 ± 8.4 (11.30).15Initial VA20/56 ± 20/74 (20/66)20/47 ± 20/133 (20/57)20/46 ± 20/87 (20/44)20/40 ± 20/100 (20/33).30Final VA20/74 ± 20/71 (20/160)20/66 ± 20/83 (20/89)20/65 ± 20/95 (20/80)20/54 ± 20/77 (20/66).60*Data are given as mean ± SD (median). VA indicates visual acuity. Comparisons were made using the Kruskal-Wallis test.COMMENTFreund et alreported that approximately 13% of the CNV lesions they studied were well defined by FA, with the remaining 87% considered occult. Indocyanine green angiography is a new technique that enhances imaging of the choroid and has been shown to be useful in better delineating O-CNV. The characteristics of the dye (fluorescent in the near infrared range and almost completely protein bound) have permitted better investigation of the choroidal abnormalities through the pigmentary epithelium, hemorrhages, and turbid fluids.Indocyanine green angiography identifies the O-CNV better.It delineates focal, plaque, or mixed (focal and plaque) CNV.Focal CNV (29% of cases) is a bright, well-defined, hyperfluorescent lesion smaller than 1 disc area. Plaque is a large area of hyperfluorescence bigger than 1 disc area that may be well defined (27% of patients) or poorly defined (34% of patients).Well-defined plaques are moderately hyperfluorescent lesions with sharp borders, and they usually appear in the late phase of the ICGA, without any dye staining. Poorly defined plaques show irregular, unclear edges and often leak dye during the late phase of the examination. Plaque CNV are not usually eligible for laser treatment because of their size and frequent subfoveal location. However, ICGA has not yet permitted an evaluation of the natural course of the different types of CNV. Furthermore, new forms of presumed CNV (polypoidal CNV) are being evaluated.Evidence that plaque corresponds to CNV was provided by Chang et aland Lauer et al.These histological studies showed that plaque consists of thick fibrovascular tissue within the Bruch membrane. However, clinicopathological data on these lesions is scant, and questions remain about their histological characteristics.Poor natural evolution of CNV in ARMD is well known.Occult CNV also has a bad prognosis.We found no contributions of the natural history of focal CNV detected by ICGA, because most investigators considered ICGA-guided laser treatment effective. The natural course of hyperfluorescent plaque lesions is better known, because they are not usually treated, although results are far from uniform. In 1992, Yannuzzi et alfirst showed plaque lesions, by means of ICGA, as a vascularized retinal pigment epithelium (RPE) often associated with good VA and very slow progression; Guyer et al,however, found the natural history of plaques discouraging, with an increase of the plaque correlated with decreased VA and increased exudation.Our study confirmed that plaques tend to get bigger(Figure 2and Figure 3). We noted an increase of about 40% during a median follow-up of 11 months. There was significant VA loss during this period, but the enlargement of the plaque could explain only 6% of the variability of this loss, and multivariate analysis found the relationship was not statistically significant, probably because of the small sample size. No correlation was found between VA decline and other associated alterations such as subretinal hemorrhages and elevation of the neovascularization. There was, however, a significant correlation between patients' age and VA loss, ie, the older the patient, the worse the VA. We can explain this by the more diffuse alteration of RPE and choroid in older patients, which may affect VA. Also, greater loss of VA was seen with longer follow-up. The worsening of VA, weakly correlated to the plaque increase, was progressive; at the onset, plaque CNV was located subretinally, and retinal changes were usually slight. As the plaque became larger, however, it caused chronic damage to the RPE and neurosensorial retina.Figure 2.Red-free retinography (A) and fluorescein angiography (FA) (B) show an exudative age-related macular degeneration. A plaque choroidal neovascularization is visible in the late phases of indocyanine green angiography (ICGA) as a hyperfluorescent, well-defined area (C). Red-free retinography (D), FA (E), and ICGA (F) were performed 7 months later. The ICGA image shows approximately 300% enlargement of the plaque. Visual acuity at the beginning and 7 months later was 20/40 and 20/32, respectively.Figure 3.Red-free retinography (A), fluorescein angiography (FA) (B), and indocyanine green angiography (ICGA) (C) of an exudative maculopathy, with a well-defined plaque choroidal neovascularization visible on ICGA. D, E, and F, Red-free retinography, FA, and ICGA, respectively, 9 months later. Compared with FA (E), ICGA (F) shows considerable enlargement of the plaque. Visual acuity was unchanged (20/32).CONCLUSIONSWell-defined plaques tend to enlarge in time, growing by about 40% during 1 year of follow-up. The loss of VA is slightly, but not significantly, correlated to plaque enlargement. Plaque lesions, therefore, appear to be a less aggressive, slower developing form of CNV, with a relatively good prognosis, although the natural tendency is to worsen. Further follow-up will be necessary to establish their course, considering those that develop into well-defined, classic CNV and those that proceed to natural involution.KBFreundLAYannuzziJASorensonAge-related macular degeneration and choroidal neovascularization.Am J Ophthalmol.1993;115:786-791.DRGuyerLAYannuzziJSSlakterClassification of choroidal neovascularization by digital indocyanine green videoangiography.Ophthalmology.1996;103:2054-2060.LAYannuzziJSSlakterJASorensonDigital indocyanine green videoangiography and choroidal neovascularization.Retina.1992;12:191-223.Not AvailableSAS System Release[computer program&rsqb;.Version 6.10, 1991-1994. Cary, NC: SAS Institute Inc; 1994.LAYannuzziJASorensonDRGuyerIndocyanine green videoangiography: current status.Eur J Ophthalmol.1994;4:69-81.APeceUIntroiniGBolognesiRBrancatoIndocyanine green angiography in age-related macular degeneration with occult neovascularization.Ophthalmologica.1998;212:295-300.TSChangKBFreundZDe La CruzClinicopathologic correlation of choroidal neovascularization demonstrated by indocyanine green angiography in a patient with retention of good vision for almost four years.Retina.1994;14:114-124.AKLauerDJWilsonMLKleinClinicopathologic correlation of fluorescein and indocyanine green videoangiography in occult choroidal neovascularization (abstract).Invest Ophthalmol Vis Sci.1997;38(suppl):442.SBBresslerNMBresslerSLFineNatural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration.Am J Ophthalmol.1982;93:157-163.GSoubraneGCoscasCFrancoisFKoenigOccult subretinal new vessels in age-related macular degeneration: natural history and early laser treatment.Ophthalmology.1990;97:649-657.GBolognesiRBrancatoAPeceIndocyanine green angiography (ICGA) follow-up of plaque choroidal neovascularization in age-related macular degeneration (abstract).Invest Ophthalmol Vis Sci.1997;38(suppl):445.Accepted for publication December 9, 1999.Reprints: Rosario Brancato, MD, Department of Ophthalmology and Visual Sciences, Scientific Institute HS Raffaele, University of Milano, Via Olgettina 60, 20132 Milano, Italy (e-mail: brancato.rosario@hsr.it).

Journal

JAMA OphthalmologyAmerican Medical Association

Published: May 1, 2000

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$499/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month